Literature DB >> 3559585

Resection arthroplasty following infected total hip replacement arthroplasty.

G S Kantor, J A Osterkamp, L D Dorr, D Fischer, J Perry, J P Conaty.   

Abstract

Thirty-nine patients with 41 hips with resection arthroplasty for infected total hip replacement arthroplasty were evaluated for functional level and factors that contribute to that level. Eighty-three percent were either minimal community ambulators or nonambulators, and only two patients walked without assistive devices. At last follow-up, 93% of the patients had pain in their hips. The best function was obtained in patients with a healed wound and heterotopic ossification. The worst functional result was in patients with chronic drainage. Fifteen of the patients with resection arthroplasties had foot-switch studies to determine gait velocity and single-limb stance time. Ten patients also had oxygen consumption studies performed. The average gait velocity was 35 m/minute (41% of normal). The average oxygen consumption was 0.41 ml/gm (264% normal) with an average heart rate of 121. The energy consumption was greater than that recorded in patients with above-knee amputation.

Entities:  

Mesh:

Year:  1986        PMID: 3559585     DOI: 10.1016/s0883-5403(86)80045-6

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  8 in total

1.  Two-stage total hip arthroplasty: how often does it control methicillin-resistant infection?

Authors:  Fay Leung; Corey J Richards; Donald S Garbuz; Bassam A Masri; Clive P Duncan
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

2.  Cementless two-staged total hip arthroplasty with a short term interval period for chronic deep periprosthetic infection. Technique and long-term results.

Authors:  Jochen Erhart; Karl Jaklitsch; Mark Schurz; Vilmos Vécsei; Reinhard Ehall
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

3.  [Risk factors for failed cleansing following periprosthetic delayed hip prosthesis infection].

Authors:  U Spiegl; R Pätzold; J Friederichs; M Militz; V Bühren
Journal:  Orthopade       Date:  2012-06       Impact factor: 1.087

Review 4.  Two-stage arthroplasty for septic arthritis of the hip and knee: A systematic review on infection control and clinical functional outcomes.

Authors:  Antonio Russo; Luca Cavagnaro; Mattia Alessio-Mazzola; Lamberto Felli; Giorgio Burastero; Matteo Formica
Journal:  J Clin Orthop Trauma       Date:  2021-11-30

5.  Hip and Knee Section, Treatment, Surgical Technique: Proceedings of International Consensus on Orthopedic Infections.

Authors:  Moneer M Abouljoud; David Backstein; Andrew Battenberg; Matthew Dietz; Alejo Erice; Andrew A Freiberg; Jeffrey Granger; Adam Katchky; Anton Khlopas; Tae-Kyun Kim; Per Kjaersgaard-Andersen; Kyung-Hoi Koo; Yona Kosashvili; Percia Lazarovski; Jennifer Leighton; Adolph Lombardi; Konstantinos Malizos; Jorge Manrique; Michael A Mont; Marianthe Papanagiotoy; Rafael J Sierra; Nipun Sodhi; John Stammers; Maik Stiehler; Timothy L Tan; Katsufumi Uchiyama; Derek Ward; Anna Ziogkou
Journal:  J Arthroplasty       Date:  2018-10-19       Impact factor: 4.757

Review 6.  Salvage Procedures for Management of Prosthetic Joint Infection After Hip and Knee Replacements.

Authors:  Samer S S Mahmoud; Mohamed Sukeik; Sulaiman Alazzawi; Mohammed Shaath; Omar Sabri
Journal:  Open Orthop J       Date:  2016-11-30

7.  Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-, multidisciplinary-, and experience-based approach.

Authors:  Tristan Ferry; Cécile Batailler; Sophie Brosset; Camille Kolenda; Sylvain Goutelle; Elliot Sappey-Marinier; Jérôme Josse; Frédéric Laurent; Sébastien Lustig
Journal:  SICOT J       Date:  2020-07-07

Review 8.  Titanium-Based Hip Stems with Drug Delivery Functionality through Additive Manufacturing.

Authors:  Martin B Bezuidenhout; Dimitar M Dimitrov; Anton D van Staden; Gert A Oosthuizen; Leon M T Dicks
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.